Patients admitted to the ICU are usually in need of invasive and uncomfortable interventions such as mechanical ventilation. To reduce anxiety, increase tolerance, and improve outcomes of such interventions, sedation is common practice. 1 Traditionally, sedative agents administered in the ICU are g-aminobutyric receptor agonists (GABA) which include the benzodiazepines (usually midazolam) and propofol. 2 Optimum sedation is vital in striking a balance between providing pain relief and maintaining patient calm while preventing over-sedation and unnecessarily lengthy ICU stays. 3 Many protocols advise daily sedation interruptions to assess the level of sedative in the patient and to avoid oversedation. 4 Dexmedetomidine has been studied as an alternative to traditional GABA-based sedation in the ICU. As a selective a2-receptor agonist, it acts at the locus coeruleus and spinal cord to exert anxiolytic and sedative effects without respiratory depression. 5 Furthermore, there is evidence to suggest that administration of dexmedetomidine instead of standard sedatives (propofol or midazolam) in a critical care setting significantly reduces the incidence of delirium. 6 The United States Federal Drug Administration has, however, advised that it is only used for short-term sedation (,24 h) because of adverse effects such as tachyphylaxis, complications of respiratory failure, acute respiratory distress syndrome, and agitation associated with longer administration times. 7 Considering that the sedation needs of critically ill patients can often be for weeks at a time, this questions the suitability of dexmedetomidine as a sedative in the ICU setting. Several sedation scoring scales have been developed for the assessment of sedation level and are used in studies to assess the amount of time a patient spends within a desirable 'target range'. The Ramsey Sedation Scale (RSS) was the first standardized procedural measurement for sedation. 8 The RSS scores patients between 1 and 6, with 1 corresponding to an anxious or agitated state and 6 to no response. The Riker Sedation and Agitation Score (RSAS) is similar and scores between 1 for fully sedated and 7 for dangerously agitated. 9 The Richmond Agitation-Sedation Scale (RASS) 10 11 is a similar score which has been shown to correlate directly with other, more objective, measures of sedation such as the bispectral index (BIS). 12 Haemodynamic variables such as heart rate (HR) and arterial pressure (AP) also provide objective measures by which sedation level can be assessed, although these are subject to other physiological factors. 13 We compared the sedative and clinical effectiveness of dexmedetomidine with midazolam, used in adults admitted to ICU using an objective appraisal of randomized control trials.
Methods
Medline (1946 -present), Embase (Embase Classic+Embase, 1947 -May 15, 2012), SCOPUS, Web of Knowledge, CINAHL and the United States National Library of Medicine were searched and also the Cochrane Database of Systematic Reviews (2005 -April 2012). MeSH terms and keywords were defined as 'dexmedetomidine', 'midazolam', and 'intensive care', and these terms were combined (Fig. 1) . For Medline and Embase, the search was then limited to studies that were randomized control trials involving humans and patients aged .18 yr old. Our search encompassed papers and conference abstracts in all languages. Full texts were then retrieved for those deemed suitable and these were again assessed for relevance. References in the retrieved articles were then scrutinized for any further studies. The papers were then critically appraised. 14 
Results
Effectiveness of sedation was the main primary outcome in all six studies, though its definition varied slightly between them (Table 1) . Jakob and colleagues, 15 Riker and colleagues, 16 Riker and colleagues, 17 and Ruokonen and colleagues 18 described effectiveness as the proportion of time spent within a target sedation range (or, as explained by Jakob; 'maintaining sedation'). Senoglu and colleagues 19 defined it as achieving a target level of sedation with respect to certain measurement scales (e.g. RSS, RSAS, and BIS), and in the study by Esmaoglu and colleagues, 20 we believed it to be the duration of sedation; however, this was unclear. The pilot study by Riker and colleagues 17 was presented at a conference and is only available as an abstract with limited results. The author was contacted and suggested that a full article publication was not possible as it was a pilot study with recruitment being 'too small for any meaningful publication'. The studies by Jakob and colleagues, 15 Riker and colleagues, 16 and Ruokonen and colleagues 18 assessed patients using RASS although the target sedation ranges differed between them: Riker and colleagues used a range of 22 to 1 while Jakob and colleagues had a target range of 23 to 0. Ruokonen and colleagues 18 determined target RASS range before starting the treatment, which varied from 24/23 to 0. It cannot be ascertained from the paper how the target range was identified, but it appears to vary between study centres, although possibly between patients as well. Length of ICU stay (LOS) was used as a secondary outcome in four of our six trials (Table 2) . Only Esmaoglu and colleagues 20 found a statistically significant difference in LOS between the two drugs (P¼0.021). This was in favour of dexmedetomidine over midazolam with results of 45.5 and 83 h spent in ICU, respectively. Haemodynamic characteristics were assessed as secondary outcomes for three of the six papers, Senoglu and colleagues 19 measured the HR, AP, and arterial blood gases (ABG) of all patients during sedation. Unfortunately, the results for this study were illustrated in graphical form only and so could not be interpreted accurately. However, a lower rate for dexmedetomidine compared with midazolam was seen over the recorded 24 h period (P¼0.05). In addition to the measurement of HR, Esmaoglu and colleagues 20 also assessed mean arterial pressure (MAP). A statistically significant reduction in HR during the first 24 h was seen in the dexmedetomidine group (P,0.05), though no difference was found at 48 and 72 h. Esmaoglu and colleagues also found that patients who were sedated with dexmedetomidine had a lower MAP than those receiving midazolam between 3 and 24 h, though at 48 and 72 h the opposite was true. However, only the results from hours 5, 6, 12, and 24 h were statistically significant (P,0.05). Senoglu and colleagues reported that patients receiving dexmedetomidine had lower systolic and diastolic pressures during the first 2 h than patients who received midazolam (P,0.05). There was no statistically significant difference in AP at 4 h. ABGs were measured only in the Senoglu study, which found that in both groups Pa CO 2 decreased (P,0.05), there was no difference in Pa O 2 . The pilot study by Riker and colleagues noted that both study groups had decreases in HR, with the dexmedetomidine group showing a greater decrease (12.7 vs 2.0 bpm). Systolic AP was preserved in both groups, [ 7.1 (13. Efficacy of dexmedetomidine compared with midazolam for sedation Table 3 and an assessment for the overall risk of bias for each paper has been made.
Discussion
We could find no ideal study comparing the effectiveness of dexmedetomidine with other sedative agents commonly used on ICU. The main problem with assessing the effectiveness of sedation is that most measurements are made from subjective scales. Only one of the studies included BIS as an objective measurement. 19 Precise measurements of target sedation are therefore made subjectively with an inherent risk of interpretation bias and inconsistency. Only in one study were RSS and RSAS assessments made by the same blinded investigator to minimize inconsistency. 19 In Esmaoglu and colleagues, 20 RSS was used to ensure that patients were at an appropriate sedation level, but any record of how long patients were maintained at these target levels (2-3 on the RSS) was omitted. 'Effectiveness' of sedation perhaps meant the duration of sedation in general, which provided unreliable results as additional propofol was administered if 'sedation became inadequate (RSS,2)', and more patients in the midazolam group received additional propofol than in the dexmedetomidine group (12 vs 9). Thus, the primary outcome for this study did not present usable comparable results and was ignored in both the discussion and conclusion. In the study by Jakob and colleagues, 15 patients who were given propofol were not analysed independently from those who did not receive propofol-again leading to difficulties in accurately interpreting the conclusions. It would seem that dexmedetomidine may reduce the length of ICU stay, though only one 20 recorded a statistically significant difference between treatment groups. This result concurs with previous reviews similar to this topic. The meta-analysis by Tan and colleagues 21 notes that dexmedetomidine may reduce the length of ICU stay, though because of the limited evidence available, this is uncertain. Furthermore, there are confounding issues to consider. Two studies 16 19 seemed to include similar patients, while Esmaoglu and colleagues 20 had a very specific population (solely eclamptic patients) and this is possibly why it was the only trial to report a statistically significant result. Another confounder for this outcome was found in the trial by Jakob and colleagues 15 where the study drug was only administered between ICU days 3 and 14, though mechanical ventilation was considered in patients for up to 45 days. Before Day 3 and after Day 14, standard care was administered which was not defined. Within each of the study groups, the patients were comparable at baseline after randomization, though between studies they were not, because of different inclusion and exclusion criteria.
The results between studies may not be directly comparable and this could account for differences in LOS. Efficacy of dexmedetomidine compared with midazolam for sedation A sedative agent that can provide cardiovascular stability may be expected to be beneficial to patients in ICU. Patients who were sedated with dexmedetomidine in a trial by Frolich and colleagues 22 support the decrease in AP reported in the trials by Esmaoglu and colleagues 20 and Senoglu and colleagues. 19 A study by Ickeringill and colleagues 23 also found that dexmedetomidine decreased mean HR and mean systolic AP. Jakob and colleagues 15 concluded that patients given dexmedetomidine were more rousable, cooperative and able to communicate pain. Ruokonen and colleagues 18 concurred with this finding, although this was compared with standard care and not midazolam alone. Riker and colleagues 16 found a lower incidence of delirium and longer delirium-free duration in those on dexmedetomidine. However, they only looked for delirium while patients were taking the study drug and 48 h after cessation. Ruokonen and colleagues, 18 again comparing with standard care, found that delirium was more prevalent in the dexmedetomidine group. In the same paper, it was concluded that there was an equal need for the use of open label midazolam and fentanyl in patients in either treatment group. Though perhaps true, this may have confounded the primary outcome as the patients in the dexmedetomidine group were given midazolam and were not separated from those who did not receive it in the results. As a secondary outcome, Jakob and colleagues found that patients in the dexmedetomidine group received mechanical ventilation for less time than patients in the midazolam group. This was also found in the Ruokonen and colleagues 18 group, although was again compared with a standard care group. Riker and colleagues also found that patients were extubated sooner in the dexmedetomidine group. This paper states that patients who were not extubated, were not included in the analyses. It also fails to state whether patients who were no longer on their study drug and were extubated, were included in the analysis. However, patients in the latter study were allowed the longer maximum duration of study drug administration of 30 days.
Limitations of the studies
The six studies are clear in stating aims comparing the sedative efficacy of dexmedetomidine against that of midazolam in an ICU setting using adult patients as participants. However, the potential for confounding because of underlying disease is not clearly outlined. The international recruitment of patients seen in Riker and colleagues 16 could also lead to problems with treatment standardization. This was compensated for with a start-up meeting for all investigators and research coordinators. Here, they were trained in using the RASS and how to titrate the blinded study drug. The use of opiates vs sedation was also standardized. Having failed to provide an adequate definition of the primary outcome of 'sedation effectiveness', Esmaoglu and colleagues 20 struggled to achieve their study aim and reach reliable conclusions. Jakob and colleagues, 15 while using a recognized and validated system (RASS), do not mention blinding or single observer measurement. Senoglu and colleagues 19 reduced bias by using the same blinded investigator and BIS, although others have questioned the objectivity of this measurement. 24 Esmaoglu and colleagues 20 used RSS, but the lack of blinding by assessors must introduce bias. As non-inferiority studies, Jakob and colleagues 15 The ideal method for comparing dexmedetomidine with midazolam would be a double-blinded, randomized control trial with a study sample of sufficient size to ensure statistically significant results. We believe that this has still to be performed and we have been unable to undertake a power calculation for such a study because of a lack of variance data. The ideal assessment method would be objective and easily replicated with high sensitivity and specificity. We feel that such an assessment method does not yet exist.
In conclusion, we have carried out a systematic review comparing the sedative qualities of dexmedetomidine and midazolam for adult patients in ICU. Six randomized control trials were selected and critically appraised. Overall, evidence for the sedative superiority of dexmedetomidine over midazolam remains inconclusive and highlights the need for further, more rigorously designed trials. However, based on the literature available, dexmedetomidine appears to be a safe alternative to midazolam and may be more cost-effective.
Design
Are the aims clearly stated? Why was the study carried out? Was the sample size justified?
Formal sample size calculation carried out and detailed in the methods. Discussion-what size of effect did the study have the power to detect?
Are the measurements likely to be valid and reliable?
Methods of measurement should be described in detail. Some effort must be made to standardize methods in multicentre trials. Discuss how validity and reliability are assessed.
Could the choice of subjects influence the size of treatment effect?
The setting that patients were recruited from. Diagnostic criteria for entry to trial. Factors for exclusion from study. Description of duration and severity of disease at entry to study.
Were there ambiguities in the description of the treatment and its administration? Are the statistical methods described?
All statistical methods should be described and referenced in the methods sections. All statistical methods make some assumptions and it is encouraging if this is addressed. Lots of tests and exotic complicated statistical tests could suggest these were chosen because of the P-value they yielded. Simple methods should always be shown and compared with more complex ones. Could the lack of blinding introduce bias? Who was blinded and how was it done? How were treatments allocated? Are the outcomes clinically relevant?
